Blueprint Medicines Corp

Blueprint Medicines — Merger or Acquisition (November 2021)

8 slides from Blueprint Medicines's merger presentation, Nov 29, 2021

  1. Slide 1: Investor call to discuss planned acquisition of Lengo Therapeutics

    Celebrating our first decade of innovation in precision medicine Expanding our transformative lung cancer pipeline NOVEMEBER 29, 2021 Blueprint Medicines investor call to discuss planned acquisition of Lengo Therapeutics © 2021 Blueprint Medicines Corporation

  2. Slide 2: Forward-looking statements

    Forward - looking statements 2 This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predi

  3. Slide 3: Blueprint Medicines to acquire Lengo Therapeutics

    Blueprint Medicines to acquire Lengo Therapeutics IND, investigational new drug application. 3 LEADER IN PRECISION THERAPY LNG - 451 & RESEARCH PORTFOLIO Expands our transformative pipeline for patients with non - small cell lung cancer Adds potential best - in - class, IND - ready EGFR exon 20 prec

  4. Slide 4: LNG-451 is highly complementary to our lung cancer pipeline

    LNG - 451 is highly complementary to our lung cancer pipeline NSCLC, non - small cell lung cancer; IND, Investigational New Drug Application. * Based on preclinical models. 4 Therapeutic targets in NSCLC Program status • RET fusions and predicted resistance mutations • Approved for first - line trea

  5. Slide 5: We have expanded our opportunity to transform EGFR-driven lung cancer

    We have expanded our opportunity to transform EGFR - driven lung cancer 1 Datamonitor , SEER, Incidence and Prevalence Database, GBD 2019, WHO, IARC, RKI, Cancer Research UK, Siegel 2015 CA Cancer J Res, Sonoda 2019 Cancer Manag Res. 2 Riess 2018 J Thorac Oncol. CNS, central nervous system; Del, del

  6. Slide 6: LNG-451 has best-in-class potential

    LNG - 451 has best - in - class potential Internal company data on file. 6 Potent inhibition of all common EGFR exon 20 insertion variants Highly selective over wild - type EGFR and off - target kinases Oral administration with well - characterized preclinical pharmacology Brain penetrant with robus

  7. Slide 7: Updated as of November 29, 2021

    + Updated as of November 29, 2021 Not for promotional use. Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation. 1. Unresectable or metastatic disease. 2. CStone Pharmaceuticals has exclusive rights to develop and commercialize avaprit

  8. Slide 8: Thank you

    (Sbiveprint, Thank you

Blueprint Medicines — Merger or Acquisition (November 2021) on 6ix